Manufacturer Supply; High Quality and Competitive Price
Commercial Supply Ezetimibe (CAS: 163222-33-1) Related Intermediates:
(S)-(+)-4-Phenyl-2-oxazolidinone CAS: 99395-88-7
(R)-(+)-2-Methyl-CBS-oxazaborolidine CAS: 112022-83-0
4-(4-Fluorobenzoyl)butyric acid CAS: 149437-76-3
4-[[(4-Fluorophenyl)imino]methyl]-phenol CAS: 3382-63-6
N-(4-(Benzyloxy)benzylidene)-4-fluoroaniline CAS: 70627-52-0
(3R,4S)-4-[4-(Benzyloxy)phenyl]-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-oxopropyl]azetidin-2-one CAS 190595-65-4
(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone CAS: 189028-93-1
(4S)-3-[(5S)-5-(4-Fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one CAS: 189028-95-3
Ezetimibe CAS: 163222-33-1
| Chemical Name |
(3R,4S)-1-(4-Fluorophenyl)-3-[(S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one |
| Synonyms |
Ezetimibe |
| CAS Number |
163222-33-1 |
| CAT Number |
RF-API02 |
| Stock Status |
In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula |
C24H21F2NO3 |
| Molecular Weight |
409.43 |
| Melting Point |
162.0 ~ 166.0℃ |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White to Off-White Powder |
| Purity / Analysis Method |
98.5%~102.0% (HPLC) |
| Specific Rotation |
-25.0°~ -30.0° |
| Moisture (K.F) |
≤0.50% |
| Heavy Metals |
≤0.002% |
| Enantiomer |
≤0.30% |
| Single Max. Impurity |
≤0.50% |
| Total Impurities |
≤1.0% |
| Test Standard |
Enterprise Standard |
| Usage |
Ezetimibe (CAS: 163222-33-1) API |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Ezetimibe (CAS: 163222-33-1) is a cholesterol transport inhibitor that binds to NPC1L1, belongs to a class of substances used to lower cholesterol levels in the blood is a drug that lowers plasma cholesterol levels. It acts by decreasing cholesterol absorption in the small intestine. It may be used alone when other cholesterol-lowering medications are not tolerated, or together with statins (e.g., ezetimibe/simvastatin) when statins alone do not control cholesterol. Ezetimibe is orally administered alone or as a combination tablet with either simvastatin or atorvastatin. Ezetimibe was approved in 2002 by the FDA, under the trade name Zetia. It is approved for use in the EU as Ezetrol and other trade names. It is produced through a multi-step chemical process.